These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

383 related articles for article (PubMed ID: 34990810)

  • 1. A self-amplifying mRNA SARS-CoV-2 vaccine candidate induces safe and robust protective immunity in preclinical models.
    Maruggi G; Mallett CP; Westerbeck JW; Chen T; Lofano G; Friedrich K; Qu L; Sun JT; McAuliffe J; Kanitkar A; Arrildt KT; Wang KF; McBee I; McCoy D; Terry R; Rowles A; Abrahim MA; Ringenberg MA; Gains MJ; Spickler C; Xie X; Zou J; Shi PY; Dutt T; Henao-Tamayo M; Ragan I; Bowen RA; Johnson R; Nuti S; Luisi K; Ulmer JB; Steff AM; Jalah R; Bertholet S; Stokes AH; Yu D
    Mol Ther; 2022 May; 30(5):1897-1912. PubMed ID: 34990810
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A dual-antigen self-amplifying RNA SARS-CoV-2 vaccine induces potent humoral and cellular immune responses and protects against SARS-CoV-2 variants through T cell-mediated immunity.
    McCafferty S; Haque AKMA; Vandierendonck A; Weidensee B; Plovyt M; Stuchlíková M; François N; Valembois S; Heyndrickx L; Michiels J; Ariën KK; Vandekerckhove L; Abdelnabi R; Foo CS; Neyts J; Sahu I; Sanders NN
    Mol Ther; 2022 Sep; 30(9):2968-2983. PubMed ID: 35450821
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Low-dose self-amplifying mRNA COVID-19 vaccine drives strong protective immunity in non-human primates against SARS-CoV-2 infection.
    Rappaport AR; Hong SJ; Scallan CD; Gitlin L; Akoopie A; Boucher GR; Egorova M; Espinosa JA; Fidanza M; Kachura MA; Shen A; Sivko G; Van Abbema A; Veres RL; Jooss K
    Nat Commun; 2022 Jun; 13(1):3289. PubMed ID: 35672369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preclinical evaluation of a SARS-CoV-2 mRNA vaccine PTX-COVID19-B.
    Liu J; Budylowski P; Samson R; Griffin BD; Babuadze G; Rathod B; Colwill K; Abioye JA; Schwartz JA; Law R; Yip L; Ahn SK; Chau S; Naghibosadat M; Arita Y; Hu Q; Yue FY; Banerjee A; Hardy WR; Mossman K; Mubareka S; Kozak RA; Pollanen MS; Martin Orozco N; Gingras AC; Marcusson EG; Ostrowski MA
    Sci Adv; 2022 Jan; 8(3):eabj9815. PubMed ID: 35044832
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A next-generation intranasal trivalent MMS vaccine induces durable and broad protection against SARS-CoV-2 variants of concern.
    Xu J; Zhang Y; Qu P; Shamseldin MM; Yoo SJ; Misny J; Thongpan I; Kc M; Hall JM; Evans JP; Eltobgy M; Lu M; Ye C; Chamblee M; Liang X; Martinez-Sobrido L; Amer AO; Yount JS; Boyaka PN; Peeples ME; Liu SL; Dubey P; Li J
    Proc Natl Acad Sci U S A; 2023 Oct; 120(41):e2220403120. PubMed ID: 37796985
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vaccine-associated respiratory pathology correlates with viral clearance and protective immunity after immunization with self-amplifying RNA expressing the spike (S) protein of SARS-CoV-2 in mouse models.
    Kachko A; Selvaraj P; Liu S; Kim J; Rotstein D; Stauft CB; Chabot S; Rajasagi N; Zhao Y; Wang T; Major M
    Vaccine; 2024 Jan; 42(3):608-619. PubMed ID: 38142216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Cocktail of Lipid Nanoparticle-mRNA Vaccines Broaden Immune Responses against β-Coronaviruses in a Murine Model.
    Zhang Y; Zhang J; Li D; Mao Q; Li X; Liang Z; He Q
    Viruses; 2024 Mar; 16(3):. PubMed ID: 38543849
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical immune efficacy against SARS-CoV-2 beta B.1.351 variant by MVA-based vaccine candidates.
    Pérez P; Albericio G; Astorgano D; Flores S; Sánchez-Corzo C; Sánchez-Cordón PJ; Luczkowiak J; Delgado R; Casasnovas JM; Esteban M; García-Arriaza J
    Front Immunol; 2023; 14():1264323. PubMed ID: 38155964
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Omicron-specific mRNA vaccine induced cross-protective immunity against ancestral SARS-CoV-2 infection with low neutralizing antibodies.
    Shen KY; Yang CH; Chen CT; Ho HM; Chiu FF; Huang CY; Liao HC; Hsu CW; Yu GY; Liao CL; Chen HW; Huang MH; Liu SJ
    J Med Virol; 2023 Jan; 95(1):e28370. PubMed ID: 36458553
    [TBL] [Abstract][Full Text] [Related]  

  • 10. One dose of COVID-19 nanoparticle vaccine REVC-128 protects against SARS-CoV-2 challenge at two weeks post-immunization.
    Gu M; Torres JL; Li Y; Van Ry A; Greenhouse J; Wallace S; Chiang CI; Pessaint L; Jackson AM; Porto M; Kar S; Li Y; Ward AB; Wang Y
    Emerg Microbes Infect; 2021 Dec; 10(1):2016-2029. PubMed ID: 34651563
    [No Abstract]   [Full Text] [Related]  

  • 11. LSDV-Vectored SARS-CoV-2 S and N Vaccine Protects against Severe Clinical Disease in Hamsters.
    de Moor WRJ; Williamson AL; Schäfer G; Douglass N; Gers S; Sutherland AD; Blumenthal MJ; Margolin E; Shaw ML; Preiser W; Chapman R
    Viruses; 2023 Jun; 15(7):. PubMed ID: 37515096
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Self-amplifying RNA SARS-CoV-2 lipid nanoparticle vaccine candidate induces high neutralizing antibody titers in mice.
    McKay PF; Hu K; Blakney AK; Samnuan K; Brown JC; Penn R; Zhou J; Bouton CR; Rogers P; Polra K; Lin PJC; Barbosa C; Tam YK; Barclay WS; Shattock RJ
    Nat Commun; 2020 Jul; 11(1):3523. PubMed ID: 32647131
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of SARS-CoV-2 infection after Spike DNA or Spike DNA+Protein co-immunization in rhesus macaques.
    Rosati M; Agarwal M; Hu X; Devasundaram S; Stellas D; Chowdhury B; Bear J; Burns R; Donohue D; Pessaint L; Andersen H; Lewis MG; Terpos E; Dimopoulos MA; Wlodawer A; Mullins JI; Venzon DJ; Pavlakis GN; Felber BK
    PLoS Pathog; 2021 Sep; 17(9):e1009701. PubMed ID: 34551020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, immunogenicity and efficacy of an mRNA-based COVID-19 vaccine, GLB-COV2-043, in preclinical animal models.
    Lelis F; Byk LA; Pustylnikov S; Nguyen V; Nguyen B; Nitz M; Tarte P; Tungare K; Li J; Manna S; Maiti S; Mehta DH; Sekar N; Posadas DM; Dhamankar H; Hughes JA; Aulisa L; Khan A; Melo MB; Dey AK
    Sci Rep; 2023 Dec; 13(1):21172. PubMed ID: 38040905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A single dose of self-transcribing and replicating RNA-based SARS-CoV-2 vaccine produces protective adaptive immunity in mice.
    de Alwis R; Gan ES; Chen S; Leong YS; Tan HC; Zhang SL; Yau C; Low JGH; Kalimuddin S; Matsuda D; Allen EC; Hartman P; Park KJ; Alayyoubi M; Bhaskaran H; Dukanovic A; Bao Y; Clemente B; Vega J; Roberts S; Gonzalez JA; Sablad M; Yelin R; Taylor W; Tachikawa K; Parker S; Karmali P; Davis J; Sullivan BM; Sullivan SM; Hughes SG; Chivukula P; Ooi EE
    Mol Ther; 2021 Jun; 29(6):1970-1983. PubMed ID: 33823303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. saRNA vaccine expressing membrane-anchored RBD elicits broad and durable immunity against SARS-CoV-2 variants of concern.
    Komori M; Nogimori T; Morey AL; Sekida T; Ishimoto K; Hassett MR; Masuta Y; Ode H; Tamura T; Suzuki R; Alexander J; Kido Y; Matsuda K; Fukuhara T; Iwatani Y; Yamamoto T; Smith JF; Akahata W
    Nat Commun; 2023 May; 14(1):2810. PubMed ID: 37208330
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of stability, safety and immunogenicity of the mRNA lipid nanoparticle vaccine Iribovax® against COVID-19 in nonhuman primates.
    Zamani P; Mashreghi M; Rezazade Bazaz M; Zargari S; Alizadeh F; Dorrigiv M; Abdoli A; Aminianfar H; Hatamipour M; Zarqi J; Behboodifar S; Samsami Y; Khorshid Sokhangouy S; Sefidbakht Y; Uskoković V; Rezayat SM; Jaafari MR; Mozaffari-Jovin S
    J Control Release; 2023 Aug; 360():316-334. PubMed ID: 37355212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Live-attenuated pediatric parainfluenza vaccine expressing 6P-stabilized SARS-CoV-2 spike protein is protective against SARS-CoV-2 variants in hamsters.
    Liu X; Park HS; Matsuoka Y; Santos C; Yang L; Luongo C; Moore IN; Johnson RF; Garza NL; Zhang P; Lusso P; Best SM; Buchholz UJ; Le Nouën C
    PLoS Pathog; 2023 Jun; 19(6):e1011057. PubMed ID: 37352333
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A highly efficacious live attenuated mumps virus-based SARS-CoV-2 vaccine candidate expressing a six-proline stabilized prefusion spike.
    Zhang Y; Lu M; Mahesh KC; Kim E; Shamseldin MM; Ye C; Dravid P; Chamblee M; Park JG; Hall JM; Trivedi S; Chaiwatpongsakorn S; Kenny AD; Murthy SS; Sharma H; Liang X; Yount JS; Kapoor A; Martinez-Sobrido L; Dubey P; Boyaka PN; Peeples ME; Li J
    Proc Natl Acad Sci U S A; 2022 Aug; 119(33):e2201616119. PubMed ID: 35895717
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single Immunization with Recombinant ACAM2000 Vaccinia Viruses Expressing the Spike and the Nucleocapsid Proteins Protects Hamsters against SARS-CoV-2-Caused Clinical Disease.
    Deschambault Y; Lynch J; Warner B; Tierney K; Huynh D; Vendramelli R; Tailor N; Frost K; Sajesh B; LeBlanc K; Layne C; Lin L; Tamming L; Beniac D; Booth S; Carpenter M; Safronetz D; Li X; Kobasa D; Cao J
    J Virol; 2022 May; 96(9):e0038922. PubMed ID: 35412347
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.